Digest Network Come funziona
Network
/
Società
Br
Non verificato

Bristol Myers Squibb

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

149 comunicati stampa

Guarda tutti i comunicati
20/07/2026
Mercato del lavoro
Industria
Sanità
Tecnica
Farmaceutica
Tecnologie Varie
Scienza
Biotecnologia
Software
Salute
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
13/07/2026
Industria
Scienza
Igiene alimentare
Biotecnologia
Sanità
Farmaceutica
Salute
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
18/06/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Salute
Industria
Scienza
Farmaceutica
Biotecnologia
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
17/06/2026
Titoli e azioni
Salute
Sanità
Farmaceutica
Biotecnologia
Bristol Myers Squibb Announces Dividend
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
Press Release cover image
17/06/2026
Salute
Fitness
Medicina - Varie
Bristol Myers Squibb Appoints Mayada Al-Ahmad as General Manager for Saudi Arabia & Gulf Countries
Fonte
Bristol Myers Squibb
Emittente
PR News Wire
1.00
0
08/06/2026
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
02/06/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
01/06/2026
Cardiologia
Infanzia
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Scienza
Vetrine/Shopping
Giovani
Medicina - Varie
Industria
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
01/06/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0
29/05/2026
Eventi
Industria
Scienza
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Oncologia
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
Fonte
Bristol Myers Squibb
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0